Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05889741 · ClinicalTrials.gov registry record · Phase 2

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

A Phase 2 study of Stress Disorders, Post-Traumatic, sponsored by The University of Texas Health Science Center at San Antonio.

Recruiting
Registry status
Phase 2
Development phase
140
Enrollment target
2
Study locations

NCT05889741: Recruiting Phase 2 study of Stress Disorders, Post-Traumatic, sponsored by The University of Texas Health Science Center at San Antonio.

NCT05889741 is a Phase 2 study of Stress Disorders, Post-Traumatic that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 140 participants, roughly in line with the 154-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05889741, a Phase 2 study of Stress Disorders, Post-Traumatic, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.

RECRUITING
Registry status
Phase 2
Development phase
140 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.

Primary Outcome

A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis.

Interventions

  • DRUG Normal saline
  • DRUG Ropivacaine injection

Study Locations (2)

Texas

  • Carl R. Darnall Army Medical Center - Fort Hood
  • University of Texas Health Science Center at San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2024-02-26
Est. Completion 2027-08-31
Phase Phase 2

What NCT05889741 shows while recruiting

NCT05889741 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 154-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target.

The record links to 1 condition, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.

NCT05889741 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05889741 about?

NCT05889741 is a clinical study titled "Combining Stellate Ganglion Block With Prolonged Exposure for PTSD". The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of milita...

What is the current status of trial NCT05889741?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2024-02-26. Estimated completion is 2027-08-31.

What conditions does trial NCT05889741 study?

This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic.

What interventions are being tested in trial NCT05889741?

The interventions under investigation include: Normal saline (DRUG), Ropivacaine injection (DRUG).

Who is sponsoring clinical trial NCT05889741?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05889741 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stress Disorders, Post-Traumatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05889741's enrollment target sits among peer trials

140 23rd of 66 higher than 44 of 66 other Stress Disorders, Post-Traumatic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stress Disorders, Post-Traumatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05889741, the US trial registry maintained by the National Library of Medicine. NCT05889741 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.